The only way to know was to wait until they died
For generations, chronic traumatic encephalopathy has been a disease that only the dead could confirm — a cruel silence imposed on athletes, soldiers, and survivors who felt their minds changing but could never know why. This week, researchers in Toronto presented a radioactive imaging tracer capable of detecting CTE's distinctive tau damage in living brains, offering for the first time the possibility of a diagnosis before death. The work is early and the sample small, but the philosophical weight is immense: a shadow lifted, a question that no longer requires a life to answer.
- CTE has long trapped its sufferers in diagnostic limbo — cognitively declining, emotionally unraveling, yet unable to receive a confirmed diagnosis or access clinical trials for treatment.
- The new tracer, 18F-OXD-2314, targets the specific tau plaques of CTE rather than Alzheimer's, filling a critical gap that existing PET tools have always left open.
- In a small pilot study, retired collision-sport athletes showed significantly elevated tracer uptake in key brain regions compared to healthy volunteers, with post-mortem tissue validation confirming the signal is real.
- The research community is cautiously energized — if larger validation studies hold, the imaging could reach patients within two years and finally make CTE clinical trials possible.
- Beyond CTE, the tracer may catalyze an entirely new generation of PET compounds targeting non-Alzheimer's tau diseases, reshaping how neurodegenerative illness is understood and treated.
For decades, the only certainty available to a retired football player or a combat veteran suspecting CTE was a grim one: they would never know for sure while alive. The disease — caused by repeated head impacts and marked by tau protein plaques — could only be confirmed through post-mortem brain examination, leaving patients to watch their memory and mood deteriorate without a definitive diagnosis, without clinical trial access, without solid ground for planning their lives.
That may now be changing. Isabelle Boileau and her team at Toronto's Center for Addiction and Mental Health developed a radioactive tracer called 18F-OXD-2314, engineered specifically to bind to the tau damage pattern unique to CTE — a pattern that existing Alzheimer's-focused PET tools consistently miss. Testing it on three retired collision-sport athletes and seven healthy volunteers, they found the tracer accumulated at significantly higher levels in the athletes' brains, particularly at the gray-white matter junction. Crucially, when the same tracer was applied to brain tissue from deceased CTE patients, it lit up every single time — biological confirmation that the signal reflects genuine pathology.
The human stakes are hard to overstate. CTE causes cognitive decline, mood disturbances, impulsivity, and dementia, yet has remained a shadow diagnosis — suspected but unprovable until autopsy. Without confirmed living cases, clinical trials for potential treatments have been impossible to design or run. Boileau's team believes that with further validation, the imaging could be available within two years, unlocking those trials and potentially inspiring new tracers for other tau-related brain diseases beyond Alzheimer's.
Presented at the Society of Nuclear Medicine and Molecular Imaging's 2026 annual meeting, the study is small and the work is early. But for the athletes and veterans who have spent years wondering whether what they feel is real, it represents something profound: the first genuine possibility of an answer while they are still alive to receive it.
For decades, the only way to know for certain that someone had chronic traumatic encephalopathy was to wait until they died and examine their brain tissue. A retired football player, a former boxer, a military veteran—all could suspect the disease was ravaging their mind, could watch their memory dissolve and their mood darken, but they would never receive a definitive answer while alive. That changed this week when researchers presented a new imaging technique that can detect the telltale signs of CTE in living patients.
The breakthrough centers on a radioactive tracer called 18F-OXD-2314, designed specifically to light up the tau plaques that accumulate in CTE brains. Existing PET imaging tools were built to detect Alzheimer's disease, and they miss the particular pattern of tau damage that characterizes CTE—a disease born from repeated head impacts, the kind that accumulates in contact sports athletes, military personnel exposed to blast injuries, and victims of domestic violence. Isabelle Boileau, a senior scientist at the Center for Addiction and Mental Health in Toronto, led the research team that tested this new tracer on a small group: three retired athletes from collision sports and seven healthy volunteers.
The results were striking. When researchers scanned the brains of the athletes with suspected CTE, the new tracer accumulated in specific regions—the gray-white matter junction and the white matter itself—at levels significantly higher than in the healthy controls. To confirm they were actually seeing CTE pathology and not some artifact of the imaging process, the team also tested the tracer on brain tissue from deceased CTE patients. The signal appeared in every single case, biological proof that the tracer was binding to genuine tau damage.
What makes this moment significant is not just the science but the human stakes. CTE causes cognitive decline, mood disturbances, impulsivity, and eventually dementia. People living with suspected CTE have had no way to know their diagnosis with certainty. They could not enroll in clinical trials testing new treatments because those trials need confirmed cases. They could not plan their medical care or their lives with solid information. The disease remained a shadow diagnosis, something suspected but never proven until autopsy.
Boileau and her colleagues believe that if further validation studies confirm these early results, the imaging could be available to patients within two years. That timeline matters because it would open the door to clinical trials specifically designed to test treatments for CTE—trials that have been impossible to run when diagnosis requires death. The tracer could also establish a broader role for PET imaging in detecting other tau-related brain diseases that are not Alzheimer's, potentially sparking development of new radioactive compounds tailored to these conditions.
The research was presented at the Society of Nuclear Medicine and Molecular Imaging's 2026 annual meeting. The sample size is small, and the work is early. But for athletes and veterans who have spent years wondering whether the changes they feel in their minds are real, whether they have a disease or are simply aging, this represents the first genuine possibility of an answer while they are still alive to receive it.
Notable Quotes
If validated, this tracer could provide the first accurate in-life diagnostic biomarker for CTE and establish a clinical role for PET imaging in traumatic brain injury and sports- and military-related neurodegeneration.— Isabelle Boileau, senior scientist at the Center for Addiction and Mental Health in Toronto
The Hearth Conversation Another angle on the story
Why does it matter that we can diagnose CTE before death? Couldn't people just get treatment based on symptoms?
Because CTE has a specific pathology—tau plaques arranged in a particular way—and you can't know you have it without seeing that pattern. Symptoms alone could be depression, could be normal aging, could be something else entirely. A confirmed diagnosis changes everything about how you understand yourself.
And the old imaging tools didn't work?
They were built for Alzheimer's. Alzheimer's tau looks different, accumulates in different places. CTE tau is its own thing. You need a tracer that recognizes that specific signature.
So this tracer is the first one designed specifically for CTE?
Yes. That's what makes it first-in-class. They tested it on three retired athletes and saw the signal light up where it should. Then they confirmed it worked on actual CTE brain tissue from deceased patients.
Two years until it's available to patients—is that realistic?
That's what the lead researcher said, pending further validation studies. It's optimistic but not impossible. The early data is very clean. But they'll need to test it on more people, make sure it's reproducible, work through regulatory approval.
Who benefits most from this?
Contact sports athletes, military veterans, domestic violence survivors—anyone whose brain has been repeatedly impacted. Right now they're the ones most likely to develop CTE and have no way to know during life. This gives them answers.